Mode
Text Size
Log in / Sign up
N/A Completed N=180 Randomized Single-blind Treatment

Xpede Clinical Study

Pathological Fracture of Vertebra Due to Secondary Osteoporosis (Disorder) · Pathological Fracture of Vertebra Due to Neoplastic Disease (Disorder)
Source: ClinicalTrials.gov NCT03730207 ↗
Enrolled (actual)
180
Serious AEs
1.1%
Results posted
Jan 2023
Primary outcomePrimary: The Change of Numerical Rating Scale (NRS) Score From Baseline at 6 Months Postoperative — -4.2; -4.4 score

Summary

The purpose of this clinical study is to confirm the efficacy and safety of the Kyphon®Xpede™ Bone Cement in human use in China.

Outcome Measures

OutcomeResultp-value
PRIMARY
The Change of Numerical Rating Scale (NRS) Score From Baseline at 6 Months Postoperative
-4.2; -4.4
PRIMARY
The Change of Index Vertebral Body Angle From Baseline at 6 Months
-0.869; -0.952
SECONDARY
The Change of NRS Score From Baseline at 1 Day and 3 Months
-2.9; -2.3; -3.6; -3.8
SECONDARY
The Change of Oswestry Disability Index (ODI) Score From Baseline at 1 Day, 3 Months, and 6 Months
-26.407; -29.108; -26.407; -29.108; -1.757; 1.746
SECONDARY
The Change of SF-36 From Baseline at 1 Day, 3 Months, and 6 Months
3.781; -1.436; 5.740; 0.086; 0.650; 0.809
SECONDARY
Change in Vertebral Body Height at 1 Day, 3 Months, and 6 Months
-4.271; -4.429; -3.949; -4.154; -2.514; -2.738
SECONDARY
Change in Vertebral Body Angle From Baseline at 1 Day and 3 Months
-1.710; -1.662; -2.739; -2.375
SECONDARY
Number of Participants With Adverse Events Reported Through 6 Months
28; 32

Eligibility Criteria

Inclusion Criteria

  • Subject being diagnosed as having painful pathological vertebral body fracture, who is suitable for VP/BKP procedure (1-3 levels) according to clinic practice.
  • Subjects who are willing to participate in study through consent and willing to undergo study specific required procedures with expectancy of geographically stable for follow up duration.
  • Subjects are at least 18 and ≤80 years old .

Exclusion Criteria

  • Subject has a local or systemic infection.
  • Subject has pains caused by other spine disease than painful pathological vertebral compression fracture.
  • Subject has a medical condition with less than 1 year of life expectancy.
  • Subject is grossly obese, i.e. BMI≥40.
  • Subject has medical conditions that represent contraindications for the use of bone cement by investigator's decision.
  • Subject has an allergy or an intolerance to bone cement component.
  • Subject has past spinal surgeries at the target level(s) for which the VP/BKP procedure is suitable.
  • Subjects who are currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study. Co-enrollment in concurrent trials is only allowed when document pre-approval is obtained from the Medtronic study manager and Medtronic Medical Advisor.
  • Pregnant women or breastfeeding women, or women of child bearing potential who are not on a reliable form of birth regulation method or abstinence.
  • Subjects with exclusion criteria required by local law (age or other).
  • Subjects with medical condition which precludes them from participation in the opinion of the Investigator.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03730207). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search